Molecular and electrophysiological bases of catecholaminergic polymorphic ventricular tachycardia.
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmogenic disorder characterized by adrenergically mediated polymorphic ventricular tachyarrhythmias. Genetic investigations have identified two variants of the disease: an autosomal dominant form associated with mutations in the gene encoding the cardiac ryanodine receptor (RyR2) and a recessive form associated with homozygous mutations in the gene encoding the cardiac isoform of calsequestrin (CASQ2). Functional characterization of mutations identified in the RyR2 and CASQ2 genes has demonstrated that CPVT are caused by derangements of the control of intracellular calcium. Investigations in a knock-in mouse model have shown that CPVT arrhythmias are initiated by delayed afterdepolarizations and triggered activity. In the present article, we review clinical and molecular understanding of CPVT and discuss the most recent approaches to develop novel therapeutic strategies for the disease.
Mohamed
Uwais
U
Division of Cardiology, Department of Medicine, London Health Science Centre, London, Canada.
Napolitano
Carlo
C
Priori
Silvia G
SG
D000818:Animals; D002395:Catecholamines / Q000502:physiology*; D022062:Electrophysiologic Techniques, Cardiac / Q000379:methods*; D006801:Humans; D011110:Polymorphism, Genetic / Q000502:physiology*; D019837:Ryanodine Receptor Calcium Release Channel / Q000502:physiology; D017180:Tachycardia, Ventricular / Q000235:genetics* / Q000503:physiopathology* / Q000628:therapy
D002395:Catecholamines; D019837:Ryanodine Receptor Calcium Release Channel